Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).

被引：0
|
作者：
Beran, H [1 ]
Giles, FJ [1 ]
Cortes, JE [1 ]
Thomas, DA [1 ]
Koller, C [1 ]
O'Brien, SM [1 ]
Keating, MJ [1 ]
Freireich, E [1 ]
Kantarjian, HM [1 ]
Estey, E [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4213
引用
收藏
页码：226B / 226B
页数：1
相关论文
共 50 条
  • [1] Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    Cortes, J
    Estey, E
    Beran, M
    O'Brien, S
    Giles, F
    Koller, C
    Keating, M
    Kantarjian, H
    LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) : 479 - 484
  • [2] Modified topotecan combination with cyclophosphamide and ara-c (CAT) for patients with Refractory/Relapsed leukemia
    Wu, Sui-jing
    Du, Xin
    Lin, Wei
    Huang, Zi-lun
    Zhou, Xiao-li
    Weng, Jian-yu
    Zhong, Li-ye
    Lu, Ze-sheng
    BLOOD, 2007, 110 (11) : 157B - 157B
  • [3] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [4] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
  • [5] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Richard L Momparler
    Experimental Hematology & Oncology, 2 (1)
  • [6] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Momparler, Richard L.
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
  • [7] Idarubicin, ara-c, and topotecan in patients with refractory or relapased acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Min, YH
    Jang, JH
    Lee, ST
    Hahn, JS
    Ko, YW
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [8] Treatment of newly-diagnosed AML and MDS with cyclophosphamide, Ara-C, topotecan.
    Estey, E
    Kantajian, H
    Giles, F
    Beran, M
    BLOOD, 1998, 92 (10) : 232A - 232A
  • [9] Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
    Kadia, Tapan M.
    Ravandi, Farhad
    Molica, Matteo
    Bataller, Alex
    Borthakur, Gautam
    Daver, Naval
    Jabbour, Elias
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Ferrajoli, Alessandra
    Ylimaz, Musa
    Bose, Prithviraj
    Tidwell, Rebecca Slack
    Marx, Kayleigh R.
    Rausch, Caitlin R.
    Kanagal-Shamanna, Rashmi
    Wang, Sa
    Islam, Rabiul
    Champlin, Richard
    Shpall, Elizabeth
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1711 - 1720
  • [10] Personalization of Induction Therapy for Pediatric AML to Ara-C plus Dauno plus Etoposide (ADE) or Clofarabine plus Ara-C According to a Polygenic Ara-C SNP Score-ACS10
    Lamba, Jatinder K.
    Marrero, Richard J.
    Elsayed, Abdelrahman H.
    Cao, Xueyuan
    Wu, Huiyun
    Inaba, Hiroto
    Raimondi, Susana C.
    Pui, Ching-Hon
    Ribeiro, Raul C.
    Rubnitz, Jeffrey E.
    Pounds, Stanley B.
    BLOOD, 2022, 140 : 1039 - 1040
12345